INOVIQ announced the grant of two US patents during the reporting period, one for the SubB2M technology and the other for hTERT. – Patent no. 11371033 entitled ‘Subtilase cytotoxin B subunit mutant’ was issued by the United States Patent and Trademark Office, enforcing intellectual property protection in the USA for the SubB2M technology until the date of expiry in 2038. This patent provides intellectual property protection in the key US market where the SubB2M tests are planned to be first commercialised. – Patent no. 11391738 entitled ‘Method of detecting cancer’, a continuation of US patent 10,338,072, was issued by the United States Patent and Trademark Office, providing additional coverage for our hTERT assay for telomerase‐based detection of cancers other than bladder cancer (such as thyroid and breast cancer) until 2035. Patent Family Title Granted Pending Expiry SubB2M PCT/AU2017/051230 (WO2018/085888) Subtilase cytotoxin B subunit mutant AU, JP, US BR, CA, CN, EP, IN, KR, US(cont) 2037 PCT/AU2022/050470 (WO2022/236383) Methods of analysing a sample 2042 Molecular NETs PCT/US2010/058086 (WO2011/066449) Devices for detection of analytes CN, US(cont1), US(cont2), US(cont3) US(cont5) 2030 PCT/US2013/049779 (WO2014/011673) Molecular Nets EP 2033 PCT/AU2022/050428 (WO2022/232886) Methods relating to tumour-derived extracellular vesicles 2042 BARD1 PCT/FR01/02731 (WO/2002/018536) Truncated BARD1 protein, and its diagnostic and therapeutic uses US 2024 PCT/IB2011/054194 (WO/2012/038932) Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof EP, US, US(cont) 2031 EP14002398.7 Non-coding RNA as diagnostic marker and treatment target US 2035 hTERT PCT/AU2015/050060 (WO2015/120523) Method of resolving inconclusive cytology to detect cancer AU, CN, EP, IL, JP, US, US(cont) 2035 PCT/AU2016/050764 (WO2017/027928) Method of detecting cancer in morphologically normal cells JP US 2036 CORPORATE UPDATE INOVIQ continued to drive awareness of its enhanced investment proposition, multi-product pipeline, progress and plans with investors and media through the period. INOVIQ presented at multiple investor conferences and numerous media outlets reported on INOVIQ news, see Presentation tab www.inoviq.com/site/investors/presentations and Media tab www.inoviq.com/site/media/inoviq-in-the-news. 17 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3